LianBio (NASDAQ:LIAN – Get Rating) Director Perceptive Advisors Llc purchased 120,000 shares of LianBio stock in a transaction that occurred on Wednesday, May 25th. The shares were bought at an average price of $2.63 per share, for a total transaction of $315,600.00. Following the transaction, the director now owns 2,661,251 shares in the company, valued at $6,999,090.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Perceptive Advisors Llc also recently made the following trade(s):

• On Monday, May 23rd, Perceptive Advisors Llc purchased 8,700 shares of LianBio stock. The shares were purchased at an average cost of $2.49 per share, with a total value of $21,663.00.

LianBio stock traded up $0.19 during mid-day trading on Wednesday, reaching $2.67. 262,148 shares of the stock traded hands, compared to its average volume of 452,204. The firm’s 50-day simple moving average is $3.75. LianBio has a 12-month low of $2.15 and a 12-month high of $16.37.

LianBio (NASDAQ:LIAN – Get Rating) last announced its quarterly earnings results on Wednesday, March 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.44. Equities research analysts anticipate that LianBio will post -1.2 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC bought a new position in shares of LianBio during the fourth quarter valued at approximately $68,000. CNA Financial Corp bought a new position in LianBio during the fourth quarter worth about $99,000. Vident Investment Advisory LLC acquired a new stake in shares of LianBio in the first quarter valued at approximately $74,000. Point72 Hong Kong Ltd acquired a new position in shares of LianBio in the 4th quarter valued at $123,000. Finally, MYDA Advisors LLC bought a new stake in LianBio during the 4th quarter worth about $123,000. 83.37% of the stock is owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research cut LianBio from a “hold” rating to a “sell” rating in a research report on Tuesday, April 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $23.19.

About LianBio (Get Rating)

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn’s disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.

Featured Articles

Receive News & Ratings for LianBio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for LianBio and related companies with MarketBeat.com’s FREE daily email newsletter.